-

Vicarious Surgical Announces Cleanroom Qualification for Manufacturing of the Vicarious System

WALTHAM, Mass.--(BUSINESS WIRE)--Vicarious Surgical, Inc. (“Vicarious Surgical” or the “Company”), a next-generation robotics company seeking to improve the cost, efficiency, and outcomes of surgical procedures, today announced qualification of its cleanroom for manufacturing of the Vicarious System.

The cleanroom substantially augments the company’s existing capabilities by providing an environmentally controlled and easily expandable space for precision assembly. Through rigorous testing, the qualification process ensures the space meets stringent efficiency and quality criteria. Cleanroom qualification is an essential step in the manufacturing process for the Vicarious System.

“Our commitment to improving patient outcomes, increasing the efficiency of surgical procedures, and reducing healthcare costs drives everything we do – and that commitment starts with a safe, quality-controlled manufacturing process before the Vicarious System reaches the operating room,” said Adam Sachs, CEO and co-founder of Vicarious Surgical. “Completing our cleanroom facility ensures we are prepared to develop and finalize our system safely, a critical milestone on our path to bringing our solution to market.”

The Vicarious System is designed with a focus on abdominal access and visualization to perform surgical procedures through a single port, offering surgeons unprecedented visualization, surgical site access, and ease of use to enable more consistent and precise procedures, faster patient recoveries, and ultimately better outcomes. The system is portable and can be moved from one operating room to another.

About Vicarious Surgical

Founded in 2014, Vicarious Surgical is a next generation robotics company developing a disruptive technology with the goals of increasing the efficiency of surgical procedures, improving patient outcomes, and reducing healthcare costs. The Company’s novel surgical approach uses proprietary human-like surgical robots to transport surgeons inside the patient to perform minimally invasive surgery. The Company is led by an experienced team of technologists, medical device professionals and physicians, and is backed by technology luminaries including Bill Gates, Vinod Khosla’s Khosla Ventures, Innovation Endeavors, Jerry Yang’s AME Cloud Ventures, Sun Hung Kai & Co. Ltd and Philip Liang’s E15 VC. The Company is headquartered in Waltham, Massachusetts. Learn more at www.vicarioussurgical.com.

Contacts

Media Inquiries
Jill Gross for Matter Health
media@vicarioussurgical.com

Investor Contact
Marissa Bych
Gilmartin Group
ir@vicarioussurgical.com

Vicarious Surgical, Inc.

NYSE:RBOT

Release Versions

Contacts

Media Inquiries
Jill Gross for Matter Health
media@vicarioussurgical.com

Investor Contact
Marissa Bych
Gilmartin Group
ir@vicarioussurgical.com

More News From Vicarious Surgical, Inc.

Vicarious Surgical Reports Fourth Quarter and Full Year 2025 Financial Results

WALTHAM, Mass.--(BUSINESS WIRE)--Vicarious Surgical Inc. (“Vicarious Surgical” or the “Company”) (OTCID: RBOT), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced financial results for the fourth quarter and full year ended December 31, 2025. Fourth Quarter 2025 Financial Results Total operating expenses were $9.3 million in the fourth quarter of 2025, and $15.0 million in the fourth quarter of 2024, a decrease of 38%. Researc...

 Vicarious Surgical Receives Delisting Notice From NYSE

WALTHAM, Mass.--(BUSINESS WIRE)--Vicarious Surgical Inc. (NYSE: RBOT) (the “Company”), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced that on March 3, 2026, it received a notice (the “Notice”) from the New York Stock Exchange (the “NYSE”) that the NYSE has commenced the process of delisting the Company’s Class A common stock, par value $0.0001 per share (the “Common Stock”). Trading on the Company’s Common Stock on the NYS...

Vicarious Surgical Advances Toward Design Freeze with Successful In-Vivo Porcine Lab

WALTHAM, Mass.--(BUSINESS WIRE)--Vicarious Surgical (NYSE: RBOT) (the “Company”), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced the successful completion of an in-vivo porcine lab conducted in December 2025, marking a meaningful step forward in the development of the company’s robotic system and reinforcing progress toward system design freeze targeted for the end of 2026. During the lab, surgeons independently completed...
Back to Newsroom